These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1008 related items for PubMed ID: 24295639

  • 1. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD.
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [Abstract] [Full Text] [Related]

  • 2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [Abstract] [Full Text] [Related]

  • 3. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
    Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH, Robson S, Makrutzki M, Antic V, Brown MP.
    Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
    [Abstract] [Full Text] [Related]

  • 4. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
    Harding JJ, Catalanotti F, Munhoz RR, Cheng DT, Yaqubie A, Kelly N, McDermott GC, Kersellius R, Merghoub T, Lacouture ME, Carvajal RD, Panageas KS, Berger MF, Rosen N, Solit DB, Chapman PB.
    Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
    [Abstract] [Full Text] [Related]

  • 5. Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience.
    Arance AM, Berrocal A, Lopez-Martin JA, de la Cruz-Merino L, Soriano V, Martín Algarra S, Alonso L, Cerezuela P, La Orden B, Espinosa E.
    Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
    [Abstract] [Full Text] [Related]

  • 6. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guérin A, Yim YM.
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
    Czirbesz K, Gorka E, Balatoni T, Pánczél G, Melegh K, Kovács P, Gézsi A, Liszkay G.
    Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
    [Abstract] [Full Text] [Related]

  • 8. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Geukes Foppen MH, Boogerd W, Blank CU, van Thienen JV, Haanen JB, Brandsma D.
    Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
    [Abstract] [Full Text] [Related]

  • 9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 10. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM.
    BioDrugs; 2012 Oct 01; 26(5):325-34. PubMed ID: 22946753
    [Abstract] [Full Text] [Related]

  • 11. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
    Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB.
    Eur J Cancer; 2015 Mar 01; 51(5):642-52. PubMed ID: 25690538
    [Abstract] [Full Text] [Related]

  • 12. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.
    Lancet Oncol; 2018 Oct 01; 19(10):1315-1327. PubMed ID: 30219628
    [Abstract] [Full Text] [Related]

  • 13. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC, Matalka MS.
    Clin Ther; 2012 Jul 01; 34(7):1474-86. PubMed ID: 22742884
    [Abstract] [Full Text] [Related]

  • 14. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
    Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard J, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril M, Goldwasser F, Mortier L, Dupin N, Blanchet B.
    Target Oncol; 2016 Feb 01; 11(1):59-69. PubMed ID: 26208946
    [Abstract] [Full Text] [Related]

  • 15. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.
    N Engl J Med; 2015 Jan 01; 372(1):30-9. PubMed ID: 25399551
    [Abstract] [Full Text] [Related]

  • 16. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA.
    Lancet Oncol; 2014 Aug 01; 15(9):954-65. PubMed ID: 25037139
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
    Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB.
    Eur J Cancer; 2015 Jul 01; 51(11):1435-43. PubMed ID: 25980594
    [Abstract] [Full Text] [Related]

  • 18. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J.
    Lancet Oncol; 2016 Sep 01; 17(9):1248-60. PubMed ID: 27480103
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
    McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A.
    Lancet Oncol; 2014 Mar 01; 15(3):323-32. PubMed ID: 24508103
    [Abstract] [Full Text] [Related]

  • 20. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
    Dzienis MR, Atkinson VG.
    Melanoma Res; 2014 Aug 01; 24(4):349-53. PubMed ID: 24709889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.